Microplate Spectrophotometer
The Epoch 2 Microplate Spectrophotometer from BioTek Instruments has added features that include monochromator-based individual wavelength selection or wavelength scanning from 200–999 nm to accommodate a range of assays, including nucleic acid and protein quantification, enzyme-linked immunosorbent assay, microbial growth, endotoxin, reactive oxygen species assays, and enzyme kinetics.
The Epoch 2 Microplate Spectrophotometer from BioTek Instruments has added features that include monochromator-based individual wavelength selection or wavelength scanning from 200–999 nm to accommodate a range of assays, including nucleic acid and protein quantification, enzyme-linked immunosorbent assay, microbial growth, endotoxin, reactive oxygen species assays, and enzyme kinetics. New onboard software eliminates the need for a separate computer and includes predefined common protocols for rapid assay setup and recall. Custom protocol definition, storage, and selection are easily accomplished via the optional color touchscreen interface. Endpoint, kinetic, and spectral scanning applications are all available from the touchscreen; data can be output to a USB flash drive or printer.
The spectrophotometer is compatible with 6- to 384-well microplates and cuvettes as well as the company’s Take3 Micro-Volume Plate for dilution-free nucleic acid quantification in volumes as low as 2 µL. Advanced shaking profiles include linear, orbital, and double orbital, and 4-Zone incubation to 65 ºC and Condensation Control facilitate temperature-sensitive assays.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
